What changed from existing technology?
This study tested a new computer program that uses artificial intelligence to measure blood vessels in living tissues. The program was compared to traditional methods of manually counting blood vessels in three different animal models.
This study is the first to directly compare a commercial deep learning tool with manual analysis for quantifying blood vessels in multiple in vivo models.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 1
ectly comparing its performance with human assessment remain limited. IKOSA CAM is a commercially available tool built for analysis of vascular networks.
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
- 장기·실사용 검증 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Validation stage
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
The tool could potentially improve the efficiency and consistency of vascular quantification in preclinical research settings.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.